Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: gao seng who wrote (64156)	3/25/1999 12:09:00 PM
From: Ron	Respond to of 119973

Cool GRIN website: grand.com

To: gao seng who wrote (64156)	3/25/1999 12:10:00 PM
From: InAndOut	Read Replies (3) \| Respond to of 119973

GBDI and WAST - easy winners for today....

To: gao seng who wrote (64156)	3/25/1999 12:37:00 PM
From: gao seng	Respond to of 119973

SUGN on 60 minutes April 4 excerpts from todays article titled "UCLA Offers Experimental Colon Cancer Treatment" at unisci.com Rosen said he's optimistic about this experimental treatment, based on results from the previous SU5416 study. The previous study, and some of its patients, will be chronicled in a rare two-segment piece on "60 Minutes," scheduled to air April 4. SU5416 is manufactured by SUGEN Inc., a South San Francisco-based biotechnology firm. In January, SUGEN announced plans to accelerate development of SU5416, testing it on colon and lung cancers. SU5416 also is being tested on AIDS-related Kaposi's sarcoma at UCLA and other sites.